News|Articles|August 2, 2025
The Weekly Roundup: July 28-August 1
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Young dermatologists should prioritize financial planning, including early saving, insurance, and effective budgeting, to secure their future.
- AI is revolutionizing skincare by personalizing product recommendations and enhancing dermatologist-patient interactions for improved outcomes.
In case you missed it, this week we had news about Johnson & Johnson's sBLA for guselkumab structural damage data, insights from LEO Pharma on the recent delgocitinib approval, the FDA's Fast Track designation for rezpegaldesleukin, and more.
Advertisement
To stay up-to-date with the latest dermatology news, sign up to receive our
Young dermatologists should learn essential financial planning strategies to secure their future, including saving early, securing insurance, and budgeting effectively.
AI revolutionizes skin care by personalizing product recommendations, enhancing customer satisfaction, and transforming dermatologist-patient interactions for better outcomes.
Learn more about the in-depth topics covered in the July 2025 print issue of Dermatology Times.
Dermatology Times is recapping our exclusive expert interviews from the month of July.
Dermatology Times is looking back on the top stories in dermatology from the month of July.
Johnson & Johnson seeks FDA approval to update guselkumab's label, highlighting its unique ability to significantly inhibit joint damage in active psoriatic arthritis.
Nektar Therapeutics advances alopecia areata treatment with FDA's Fast Track designation for rezpegaldesleukin, targeting immune modulation in chronic hair loss.
At Elevate-Derm Summer, Buchi Neita, MCMSc, PA-C, discussed enhancing dermatologic care for patients with skin of color by recognizing characteristics in common conditions and offered strategies to build rapport with patients.
Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.
Coates addresses social determinants of health in pediatric dermatology, emphasizing their impact on treatment and patient outcomes.
Lauren Madigan, MD, shares vital insights on complex dermatology, emphasizing accurate diagnoses and the importance of diversity in dermatologic imagery.
This review of the latest dermatologic studies includes insights into emerging terbinafine-resistant trichophyton dermatophytosis, clinicodemographic features and usage of oral immunosuppressive agents in childhood and adolescent vitiligo, and more.
Delgocitinib cream recently became the first FDA-approved treatment for chronic hand eczema. Robert Spurr of LEO Pharma shares insights into what it means for providers and patients.
AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.
Explore career transitions in healthcare as PAs Renata Block, MMS, PA-C, and Jessica Dell'Aquila, MS, PA-C, share insights on professional growth and evolving roles in dermatology.
VYNE Therapeutics reveals disappointing phase 2b trial results for repibresib gel in nonsegmental vitiligo, missing key efficacy endpoints.
PC111, a novel therapy from Scinai, targets pemphigus vulgaris and SJS/TEN, offering rapid relief without immunosuppression.
Deepti Gupta, MD, emphasized SPD's focus on delivering practical clinical insights, highlighting emerging research, and fostering meaningful professional connections.
At a recent Dermatology Times Case-Based Roundtable, attendees discussed several challenging AD cases.
The open-label trial showed dusquetide produced similar results to apremilast in reducing oral ulcers, pain, and ulcer duration.
O'Dowd discusses J&J's recent NDA submission for icotrokinra in psoriasis.
Whitney Hovenic, MD, highlights alarming trends in Gen Z's sun protection habits and introduces SPOOGE, a new sunscreen brand promoting skin health.
Discover how the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai leads in innovative skin cancer care and research, celebrating a decade of excellence.
Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.
Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.
Dermatology Times has compiled a list of dermatological meetings taking place during the month of August.
Michael Somenek, MD, shares how a first-of-its-kind Galderma trial using Sculptra and Restylane helped restore volume and skin quality in patients on GLP-1 medications.
The study found no association between cutaneous events and baseline EASI scores, eosinophil counts, or IgE levels.
In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.
Whitney Hovenic, MD's new SPOOGE sunscreen hopes to engage Gen Z in sun protection, merging skincare with fun and effective sun care strategies.
Glenn Kolansky, MD, FAAD, identifies oxybenzone and fragrances as leading causes of sunscreen allergies.
Dendy Engelman, MD, FACMS, FAAD, explores the latest advancements in laser and energy-based dermatological treatments, including skin resurfacing and body contouring.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
